Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222276
Title: Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies
Author: García Castillo, María Clara
Sierra Mencía, Álvaro
Caronna, Edoardo
Toledo Alfocea, Daniel
Jaimes, Alex
Urtiaga, Saray
Casas Limón, Javier
Muñoz Vendrell, Albert
Santos Lasaosa, Sonia
García Martín, Valvanuz
Martín Ávila, Guillermo
Polanco, Marcos
Villar Martínez, María Dolores
Trevino Peinado, Cristina
Rubio Flores, Laura
Sánchez Soblechero, Antonio
Portocarrero Sánchez, Leonardo
Luque Buzo, Elisa
Lozano Ros, Alberto
Gago Veiga, Ana Beatriz
Díaz de Terán, Javier
Recio García, Andrea
Canales Rodríguez, Javiera
Gómez García, Andrea
González Salaices, Marta
Campoy Diaz, Sergio
Mínguez Olaondo, Ane
Maniataki, Stefania
González Quintanilla, Vicente
Porta Etessam, Jesús
Cuadrado, María Luz
Guerrero Peral, Ángel Luis
Pozo Rosich, Patricia
Rodríguez Vico, Jaime
Huerta Villanueva, Mariano
Pascual, Julio
Goadsby, Peter J.
González Martínez, Alicia
Keywords: Migranya
Immunofarmacologia
Migraine
Immunopharmacology
Issue Date: 3-Jun-2025
Publisher: Springer Science and Business Media LLC
Abstract: Background Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. Methods This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the > 50% response rate. Moreover, autoimmune disease progression was also evaluated. We explored differences between patients with and without autoimmune disease activation. Results Among 89 patients, there were 80 (90%) females with a mean age of 50 years (SD: 11), who had a high prevalence of psychiatric comorbidities (anxiety 44%, depression 49%) and medication overuse (68%). Patients receiving immunological treatments experienced significant reductions in MMD and MHD, with MMD decreasing from 16 (SD: 7) at baseline to 9 (SD: 8) at 6 months, and MHD dropping from 23 (SD: 8) to 17 (SD: 11). A 50% response in MMD was achieved by 46% at 6 months. TEAEs were reported in 28%, most commonly constipation (16%) and dizziness (9%). Conclusions CGRP-mAbs therapies combined with immunological treatments appear effective and safe in patients with autoimmune diseases. Larger prospective studies are necessary to confirm these findings and optimize management strategies.
Note: Reproducció del document publicat a: https://doi.org/10.1007/s00415-025-13177-y
It is part of: Journal of Neurology, 2025, vol. 272, num. 6, 443
URI: https://hdl.handle.net/2445/222276
Related resource: https://doi.org/10.1007/s00415-025-13177-y
ISSN: 1432-1459
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s00415-025-13177-y.pdf773.45 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons